Abstract
Rhabdomyosarcoma (RMS) represents the most common orbital malignancy in children; patients with this disease often present to the ophthalmologist. Because current therapeutic regimens offer an excellent chance for curing isolated orbital disease, prompt diagnosis and treatment are essential. Four decades ago, the standard of care for these tumors was exenteration. Even with exenteration, survival was poor. Much of the success in reducing the morbidity and mortality over the past three decades has been through the collaborative efforts of the Intergroup Rhabdomyosarcoma Studies (IRS) formulated in the 1970s. Treatment of RMS with multiple modalities has transformed the dismal 25% 3-year life expectancy of the 1960s to overall survival (OS) rates of higher than 90% today. With such success, clinicians now have the opportunity to focus on minimizing the serious late sequelae of aggressive therapy.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Young JL Jr, Ries LG, Silverberg E, et al. Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer. 1986;58:598–602.
Friedrich P, Ortiz R, Strait K, et al. Pediatric sarcoma in Central America: outcomes, challenges, and plans for improvement. Cancer. 2012;119(4):871–9.
Howard GM, Casten VG. Rhabdomyosarcoma of the orbit in brothers. Arch Ophthalmol. 1963;70:319–22.
Dagher R, Helman L. Rhabdomyosarcoma: an overview. Oncologist. 1999;4(1):34–44.
Shields CL, Shields JA, Honavar SG, et al. Clinical spectrum of primary ophthalmic rhabdomyosarcoma. Ophthalmology. 2001;108(12):2284–92.
Hasegawa T, Matsuno Y, Niki T, et al. Second primary rhabdomyosarcomas in patients with bilateral retinoblastoma: a clinicopathologic and immunohistochemical study. Am J Surg Pathol. 1998;22(11):1351–60.
Gripp KW. Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet. 2005;137C(1):72–7.
Gripp KW, Lin AE, Stabley DL, et al. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A. 2006;140:1):1–7.
Kerr B, Delrue MA, Sigaudy S, et al. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet. 2006;43(5):401–5.
Moschovi M, Touliatou V, Papadopoulou A, et al. Rhabdomyosarcoma in a patient with Noonan syndrome phenotype and review of the literature. J Pediatr Hematol Oncol. 2007;29(5):341–4.
Samuel DP, Tsokos M, DeBaun MR. Hemihypertrophy and a poorly differentiated embryonal rhabdomyosarcoma of the pelvis. Med Pediatr Oncol. 1999;32(1):38–43.
Trahair T, Andrews L, Cohn RJ. Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma. Pediatr Blood Cancer. 2007;48(3):345–8.
Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther. 2002;1(2):97–104.
Singh AD, Traboulsi EI, Reid J, et al. Orbital cyst: prenatal diagnosis. Ophthalmology. 2009;116:2042–42.e2.
Eghtedari M, Farsiani AM, Bordbar MR. Congenital orbital rhabdomyosarcoma. Ocul Oncol Pathol. 2018;4:165–9.
Ahmad TY, Al Houri HN, Al houri AN, et al. Aggressive orbital rhabdomyosarcoma in adulthood: a case report in a public hospital in Damascus, Syria. Avicenna J Med. 2018;8(3):110–3.
Kaliaperumal S, Tiroumal S, Rao V. Orbital rhabdomyosarcoma: a case series. Indian J Cancer. 2007;44:104–7.
Garduño-Vieyra L, Hernandez-Da Mota SE, Gonzalez CR, et al. Rhabdomyosarcoma in an elderly patient. A case report. Rev Mex Oftalmol. 2017;91:73.
Wu TH, Huang JS, Wang HM, et al. Long-term survivors of adult rhabdomyosarcoma of maxillary sinus following multimodal therapy: case reports and literature reviews. Chang Cung Med J. 2010;33:466–71.
Joo JH, Han JS, Choi SM, et al. One-year survivor of adult alveolar rhabdomyosarcoma of themaxillary sinus with orbital extension: case report. Medicine. 2018;97(35):e11866.
Belyea B, Kephart JG, Blum J, et al. Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma. 2012;2012:406239.
Chung EM, Smirniotopoulos JG, Specht CS, et al. From the archives of the AFIP: pediatric orbit tumors and tumor-like lesions: nonosseous lesions of the extraocular orbit. Radiographics. 2007;27(6):1777–99.
Mafee MF, Pai E, Philip B. Rhabdomyosarcoma of the orbit. Evaluation with MR imaging and CT. Radiol Clin N Am. 1998;36(6):1215–27. xii.
Shields JA, Shields CL. Rhabdomyosarcoma: review for the ophthalmologist. Surv Ophthalmol. 2003;48(1):39–57.
Napolitano L, Howard J. Electron microscopic observations on non-specific lead staining in the small intestine of the cat after lipid or carbohydrate feeding. Anat Rec. 1968;160(1):25–35.
Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma–genotypic and phenotypic determinants of diagnosis: a report from the Children’s Oncology Group. Am J Pathol. 2009;174(2):550–64.
Fine SW, Lisanti MP, Argani P, et al. Caveolin-3 is a sensitive and specific marker for rhabdomyosarcoma. Appl Immunohistochem Mol Morphol. 2005;13(3):231–6.
Dasgupta R, Fuchs R, Rodeberg D. Rhabdomyosarcoma. Semin Pediatr Surg. 2016;25:276–83.
Raney RB, Anderson JR, Kollath J, et al. Late effects of therapy in 94 patients with localized rhabdomyosarcoma of the orbit: report from the Intergroup Rhabdomyosarcoma Study (IRS)-III, 1984–1991. Med Pediatr Oncol. 2000;34(6):413–20.
Pappo AS, Crist WM, Kuttesch J, et al. Tumor-cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. The Intergroup Rhabdomyosarcoma Study Committee of the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 1993;11(10):1901–5.
Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2002;20(11):2672–9.
Lawrence W Jr, Anderson JR, Gehan EA, et al. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children’s Cancer Study Group. Pediatric Oncology Group. Cancer. 1997;80(6):1165–70.
Adesina OO, Zaugg BE, Dries DC, et al. Undifferentiated nonrhabdomyosarcoma soft tissue sarcoma of the orbit. Ophthalmic Plasti Reconstr Surg. 2017;33(3):e57–60.
De Niro JE, Cham EM, Silkiss RZ. Undifferentiated sarcoma of the orbit with angiomyxoid features. J Pediatr Ophthalmol Strabismus. 2014;51:e4–7.
Gosiengfiao Y, Reichek J, Walterhouse D. What is new in rhabdomyosarcoma management in children? Paediatr Drugs. 2012;14(6):389–400.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Perry, J.D., Patel, B.C.K. (2019). Orbital Rhabdomyosarcoma. In: Hwang, C.J., Patel, B.C., Singh, A.D. (eds) Clinical Ophthalmic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-13558-4_17
Download citation
DOI: https://doi.org/10.1007/978-3-030-13558-4_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-13557-7
Online ISBN: 978-3-030-13558-4
eBook Packages: MedicineMedicine (R0)